Analysing the efficacy and tolerability of dolutegravir plus either rilpivirine or lamivudine in a multicentre cohort of virologically suppressed PLWHIV.

MLA

Ciccullo, A., et al. “Analysing the Efficacy and Tolerability of Dolutegravir plus Either Rilpivirine or Lamivudine in a Multicentre Cohort of Virologically Suppressed PLWHIV.” Journal of Antimicrobial Chemotherapy (JAC), vol. 78, no. 1, Jan. 2023, pp. 117–21. EBSCOhost, https://doi.org/10.1093/jac/dkac362.

APA

Ciccullo, A., Baldin, G., Borghi, V., Cossu, M. V., Giacomelli, A., Lagi, F., Farinacci, D., Iannone, V., Passerotto, R. A., Capetti, A., Sterrantino, G., Mussini, C., Antinori, S., & Giambenedetto, S. D. (2023). Analysing the efficacy and tolerability of dolutegravir plus either rilpivirine or lamivudine in a multicentre cohort of virologically suppressed PLWHIV. Journal of Antimicrobial Chemotherapy (JAC), 78(1), 117–121. https://doi.org/10.1093/jac/dkac362

Chicago

Ciccullo, A, G Baldin, V Borghi, M V Cossu, A Giacomelli, F Lagi, D Farinacci, et al. 2023. “Analysing the Efficacy and Tolerability of Dolutegravir plus Either Rilpivirine or Lamivudine in a Multicentre Cohort of Virologically Suppressed PLWHIV.” Journal of Antimicrobial Chemotherapy (JAC) 78 (1): 117–21. doi:10.1093/jac/dkac362.